Brett Haumann

1.1k citations

37 papers · 857 · h-index 17

Impact in

Physiology top 5%
- Asthma and respiratory diseases
- Adenosine and Purinergic Signaling
Pulmonary and Respiratory Medicine top 5%
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Respiratory and Cough-Related Research
- Inhalation and Respiratory Drug Delivery
- Respiratory Support and Mechanisms

Papers in

Pulmonary and Respiratory Medicine 19
- Chronic Obstructive Pulmonary Disease (COPD) Research 14
- Inhalation and Respiratory Drug Delivery 9
- Respiratory and Cough-Related Research 5
- Respiratory Support and Mechanisms 2
Physiology 16
- Asthma and respiratory diseases 16

Co-authors: Loretta Jacques (12 shared papers)Jan Lötvall (11 shared papers)Eric D. Bateman (10 shared papers)Ashley Woodcock (11 shared papers)Eugene R. Bleecker (10 shared papers)Courtney Crim (3 shared papers)Angela Davis (3 shared papers)Edmund J. Moran (9 shared papers)
Journals: CHEST Journal (4 papers)Respiratory Research (4 papers)Respiratory Medicine (3 papers)European Respiratory Journal (3 papers)Thorax (2 papers)
Partner nations: United States United Kingdom Sweden

In The Last Decade

Brett Haumann

37 papers receiving 842 citations

Peers

Countries citing papers authored by Brett Haumann

Since Specialization

Citations

This map shows the geographic impact of Brett Haumann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brett Haumann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brett Haumann more than expected).

Fields of papers citing papers by Brett Haumann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brett Haumann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brett Haumann. The network helps show where Brett Haumann may publish in the future.

Co-authors

The 25 scholars most cited alongside Brett Haumann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Brett Haumann Line = papers co-authored together Brett Haumann links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 37 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Evaluation of an ambulatory system for the quantification of cough frequency in patients with chronic obstructive pulmonary disease PubMed ·Michael Coyle, D. Barry Keenan, Linda S. Henderson, Michael L. Watkins, Brett Haumann, David Mayleben, Michael G. Wilson	2005	100
2	The Efficacy and Safety of the Novel Long-Acting β2 Agonist Vilanterol in Patients With COPD CHEST Journal ·Nicola A. Hanania, Gregory Feldman, W. Zachgo, Jae-Jeong Shim, Courtney Crim, Lisa Sanford, Sally Lettis, Frank Barnhart, Brett Haumann	2012	85
3	The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol European Respiratory Journal ·Jørgen Vestbo, Julie A. Anderson, Robert D. Brook, Peter M.A. Calverley, Bartolomé R. Celli, Courtney Crim, Brett Haumann, Fernando J. Martínez, Julie Yates, David E. Newby	2012	70
4	Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial Thorax ·William W. Busse, Eugene R. Bleecker, Eric D. Bateman, Jan Lötvall, Richard Forth, Angela Davis, Loretta Jacques, Brett Haumann, Ashley Woodcock	2011	67
5	24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids European Respiratory Journal ·Jan Lötvall, Eric D. Bateman, Eugene R. Bleecker, William W. Busse, Ashley Woodcock, Richard Follows, Jessica Lim, Sally Stone, Loretta Jacques, Brett Haumann	2012	61
6	Dose effect of once-daily fluticasone furoate in persistent asthma: A randomized trial Respiratory Medicine ·Eric D. Bateman, Eugene R. Bleecker, Jan Lötvall, Ashley Woodcock, Richard Forth, Hilary Medley, Angela Davis, Loretta Jacques, Brett Haumann, (unknown)	2012	58
7	Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids Annals of Allergy Asthma & Immunology ·Eugene R. Bleecker, Eric D. Bateman, (unknown), Ashley Woodcock, Lucy Frith, Karen House, Loretta Jacques, Angela Davis, Brett Haumann, Jan Lötvall	2012	46
8	Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma Respiratory Research ·Ashley Woodcock, Eugene R. Bleecker, (unknown), Jan Lötvall, Neil G. Snowise, Lucy Frith, Loretta Jacques, Brett Haumann, Eric D. Bateman	2011	39
9	Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial Respiratory Research ·Ashley Woodcock, Eric D. Bateman, (unknown), Jan Lötvall, Neil G. Snowise, Richard Forth, Loretta Jacques, Brett Haumann, Eugene R. Bleecker	2011	39
10	Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial BMJ Open ·Jan Lötvall, P S Bakke, Leif Bjermer, Sigurd Steinshamn, Catherine Scott-Wilson, Courtney Crim, Lisa Sanford, Brett Haumann	2012	37
11	Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies Pulmonary Pharmacology & Therapeutics ·Dean Quinn, Christopher Barnes, Wayne Yates, David L. Bourdet, Edmund J. Moran, Peter D. Potgieter, Andrew Nicholls, Brett Haumann, Dave Singh	2017	34
12	A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease Respiratory Research ·Krishna Pudi, Chris N. Barnes, Edmund J. Moran, Brett Haumann, Edward Kerwin	2017	29
13	Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease Respiratory Medicine ·James F. Donohue, Edward Kerwin, Sanjay Sethi, Brett Haumann, Srikanth Pendyala, Lorna Dean, Chris N. Barnes, Edmund J. Moran, Glenn Crater	2019	28
14	Targeting adenosine receptors in the treatment of allergic rhinitis: a randomized, double‐blind, placebo‐controlled study Clinical & Experimental Allergy ·Janet Rimmer, H.L. Peake, Cristiano Santos, Melanie L. Lean, Philip G. Bardin, Richard A. Robson, Brett Haumann, F. Loehrer, M. Händel	2006	26
15	Efficacy and optimal dosing interval of the long-acting beta2 agonist, vilanterol, in persistent asthma: A randomised trial Respiratory Medicine ·Richard K. Sterling, Jessica Lim, Lucy Frith, Neil G. Snowise, Loretta Jacques, Brett Haumann	2012	25
16	Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation ·Gary T. Ferguson, Gregory Feldman, Krishna Pudi, Chris N. Barnes, Edmund J. Moran, Brett Haumann, Srikanth Pendyala, Glenn Crater	2019	24
17	Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial Clinical Autonomic Research ·Horacio Kaufmann, Ross G. Vickery, Whedy Wang, Jitendra Kanodia, Cyndya A. Shibao, Lucy Norcliffe‐Kaufmann, Brett Haumann, Italo Biaggioni	2021	18
18	Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD) Respiratory Research ·James F. Donohue, Edward Kerwin, Sanjay Sethi, Brett Haumann, Srikanth Pendyala, Lorna Dean, Chris N. Barnes, Edmund J. Moran, Glenn Crater	2019	13
19	Evaluation of an ambulatory system for the quantification of cough frequency in patients with chronic obstructive pulmonary disease Michael Coyle, D. Barry Keenan, Linda S. Henderson, M.L. Watkins, Brett Haumann, David Mayleben, Marina Wilson	2006	10
20	Two year persistent treatment effect in reducing nasal symptoms of cat allergy after 4 doses of Cat‐PAD, the first in a new class of synthetic peptide immuno‐regulatory epitopes Clinical and Translational Allergy ·Roderick P. Hafner, Peter Couroux, Kristen Armstrong, Deepen Patel, Mark Larché, Brett Haumann	2013	7

About Brett Haumann

Brett Haumann is a scholar working on Pulmonary and Respiratory Medicine, Physiology, Surgery, Molecular Biology and Pharmacology, having authored 37 papers that have together received 857 indexed citations. Recurring topics across this work include Asthma and respiratory diseases (16 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (14 papers), Inhalation and Respiratory Drug Delivery (9 papers), Respiratory and Cough-Related Research (5 papers), Cardiovascular Syncope and Autonomic Disorders (3 papers), Respiratory Support and Mechanisms (2 papers), Plant-based Medicinal Research (1 paper) and Allergic Rhinitis and Sensitization (1 paper). The work is most often cited by research in Physiology (466 citations), Pulmonary and Respiratory Medicine (514 citations), Pharmacy (24 citations), Physiology (19 citations) and Immunology and Allergy (16 citations). Brett Haumann has collaborated with scholars based in United States, United Kingdom and Sweden. Frequent co-authors include Loretta Jacques, Jan Lötvall, Eric D. Bateman, Ashley Woodcock, Eugene R. Bleecker, Courtney Crim, Angela Davis, Edmund J. Moran, Richard Forth and Michael Coyle. Their work appears in journals such as CHEST Journal, Respiratory Research, Respiratory Medicine, European Respiratory Journal and Thorax.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Brett Haumann

Impact in

Papers in i

In The Last Decade

Brett Haumann

Peers

Countries citing papers authored by Brett Haumann

Fields of papers citing papers by Brett Haumann

All Works

About Brett Haumann

Explore authors with similar magnitude of impact

Papers in